CN115427419B - P2x3拮抗剂的制备 - Google Patents

P2x3拮抗剂的制备

Info

Publication number
CN115427419B
CN115427419B CN202180028877.XA CN202180028877A CN115427419B CN 115427419 B CN115427419 B CN 115427419B CN 202180028877 A CN202180028877 A CN 202180028877A CN 115427419 B CN115427419 B CN 115427419B
Authority
CN
China
Prior art keywords
compound
contacting
prepared
following structure
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180028877.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115427419A (zh
Inventor
N·乔雷特
杰里米·格林
大卫·R·克罗嫩塞尔
卡瑞妮·维伦纽夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
Bellus Health Cough Inc
GlaxoSmithKline Intellectual Property No 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc, GlaxoSmithKline Intellectual Property No 3 Ltd filed Critical Bellus Health Cough Inc
Publication of CN115427419A publication Critical patent/CN115427419A/zh
Application granted granted Critical
Publication of CN115427419B publication Critical patent/CN115427419B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180028877.XA 2020-02-14 2021-02-12 P2x3拮抗剂的制备 Active CN115427419B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062977004P 2020-02-14 2020-02-14
US62/977,004 2020-02-14
US202163144902P 2021-02-02 2021-02-02
US63/144,902 2021-02-02
PCT/IB2021/000130 WO2021161109A1 (en) 2020-02-14 2021-02-12 Preparation of a p2x3 antagonist

Publications (2)

Publication Number Publication Date
CN115427419A CN115427419A (zh) 2022-12-02
CN115427419B true CN115427419B (zh) 2026-04-21

Family

ID=77292130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028877.XA Active CN115427419B (zh) 2020-02-14 2021-02-12 P2x3拮抗剂的制备

Country Status (11)

Country Link
US (1) US12503470B2 (https=)
EP (1) EP4103572A4 (https=)
JP (1) JP7693691B2 (https=)
KR (1) KR20220140804A (https=)
CN (1) CN115427419B (https=)
AU (1) AU2021219992A1 (https=)
BR (1) BR112022015818A2 (https=)
CA (1) CA3184277A1 (https=)
IL (1) IL295394A (https=)
MX (1) MX2022009765A (https=)
WO (1) WO2021161109A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7578602B2 (ja) 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド Ｐ２ｘ３修飾薬での治療
WO2022156783A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
CN114805237B (zh) * 2021-01-22 2026-04-21 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist
EP4577528A1 (en) * 2022-08-25 2025-07-02 14245563 Canada Inc. Preparation of a p2x3 antagonist
WO2025125445A1 (en) 2023-12-12 2025-06-19 Glaxosmithkline Intellectual Property (No.3) Limited Process of manufacture of p2x3 antagonists including camlipixant
WO2025191081A1 (en) 2024-03-15 2025-09-18 Glaxosmithkline Intellectual Property (No.3) Limited Crystalline form of camlipixant
WO2026022326A1 (en) 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111377917A (zh) * 2018-12-29 2020-07-07 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010229142A1 (en) * 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
CN102358739B (zh) * 2011-04-29 2013-02-20 中国科学院广州生物医药与健康研究院 咪唑[1,2-a]吡啶和咪唑醛类化合物的合成方法
DK3381917T3 (da) * 2013-01-31 2021-10-18 Bellus Health Cough Inc Imidazopyridinforbindelser og anvendelser deraf
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
EP4103564A4 (en) * 2020-02-14 2024-05-01 GlaxoSmithKline Intellectual Property (No.3) Limited P2X3 MODULATORS
WO2021244634A1 (zh) 2020-06-05 2021-12-09 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
EP4169921A4 (en) 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
WO2022156783A1 (zh) 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
CN114805237B (zh) 2021-01-22 2026-04-21 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111377917A (zh) * 2018-12-29 2020-07-07 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用

Also Published As

Publication number Publication date
JP7693691B2 (ja) 2025-06-17
IL295394A (en) 2022-10-01
BR112022015818A2 (pt) 2022-10-25
MX2022009765A (es) 2022-09-09
US20230101612A1 (en) 2023-03-30
JP2023513738A (ja) 2023-04-03
KR20220140804A (ko) 2022-10-18
CA3184277A1 (en) 2021-08-19
CN115427419A (zh) 2022-12-02
EP4103572A4 (en) 2024-03-06
WO2021161109A1 (en) 2021-08-19
EP4103572A1 (en) 2022-12-21
US12503470B2 (en) 2025-12-23
AU2021219992A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN115427419B (zh) P2x3拮抗剂的制备
TWI751585B (zh) 類升糖素肽1受體促效劑
JP4249012B2 (ja) 新規な２ｈ−ピリダジン−３−オン誘導体、該誘導体を含有する医薬組成物及びこの有効成分の製法
CN117858870A (zh) P2x3拮抗剂的制备
JP2009515879A (ja) Ｔｅｃキナーゼ阻害剤
EA023955B1 (ru) Производное аминоалкилзамещенного n-тиенилбензамида
PT2334672E (pt) Compostos novos i
TW202334103A (zh) 用於治療痛風或高尿酸血症之化合物之製備
TWI555738B (zh) 苯并噻唑酮化合物
TWI659022B (zh) 作為d-胺基酸氧化酶(daao)抑制劑之新穎經取代苯并咪唑衍生物
CN120835886A (zh) S1p受体调节剂的制备
HK40084747A (en) Preparation of a p2x3 antagonist
CN119790042A (zh) P2x3拮抗剂的制备
ES2715348T3 (es) Compuestos que contienen anillos de nitrógeno fusionados para su uso como antagonistas de CRTH2
HK40113882A (zh) 用於治疗痛风或高尿酸血症的化合物的制备
TW201910332A (zh) 稠合的雙環化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084747

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240606

Address after: Kaisan ohokkatsu

Applicant after: Silvio Berlusconi health Co.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: Bellus medical cough Co.

Country or region before: Canada

TA01 Transfer of patent application right

Effective date of registration: 20240614

Address after: Kaisan ohokkatsu

Applicant after: 14245563 Canada Inc.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: Silvio Berlusconi health Co.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240705

Address after: Kaisan ohokkatsu

Applicant after: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: 14245563 Canada Inc.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240716

Address after: Steve Niki

Applicant after: GlaxoSmithKlay Intellectual Property (No.3) Co.,Ltd.

Country or region after: Britain

Address before: Kaisan ohokkatsu

Applicant before: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region before: Canada

GR01 Patent grant